by MM360 Staff | Jun 10, 2021 | Twitter
@ASCO presented by @MyMKaiser ➡️ Dara-CVRD for Ultra High Risk #myeloma and Plasmacell leukemia induces deep remissions ➡️but still with shorter PFS #ASCO21 #mmsm pic.twitter.com/mkkFPNwpdi— Suzanne Lentzsch, MD, PhD (@SLentzsch) June 8, 2021
by MM360 Staff | Jun 10, 2021 | Twitter
Some of the data presented today @ASCO will shape the future treatment of Myeloma! Will this GPRC5D TCE the rescue after BCMA treatment in #Myeloma? Congrats @BerdejaJesus on a great presentation 👏 https://t.co/i1mKY03EJS— Suzanne Lentzsch, MD, PhD (@SLentzsch) June...
by MM360 Staff | Jun 10, 2021 | Publications
The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
by MM360 Staff | Jun 10, 2021 | Publications
Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
by MM360 Staff | Jun 10, 2021 | Publications
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management […]
